PBRN18054 / ANBL1531 / Angela Girvin
Basic Study Information
Purpose:
This phase III trial studies iobenguane I-131 or crizotinib and standard therapy in
treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma.
Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor
cells and not harm normal cells. Crizotinib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or crizotinib
and standard therapy may work better compared to crizotinib and standard therapy alone
in treating younger patients with neuroblastoma or ganglioneuroblastoma.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Angela Girvin
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search